Marta P. Piras

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

Journal: Breast (Edinburgh, Scotland)

Published: February 11, 2026

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Journal: NPJ precision oncology

Published: February 03, 2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

Journal: Breast (Edinburgh, Scotland)

Published: December 22, 2025

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.

Journal: Cancer treatment reviews

Published: December 05, 2025

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.

Journal: Breast (Edinburgh, Scotland)

Published: November 12, 2025

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Journal: The oncologist

Published: June 13, 2025

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Journal: Breast (Edinburgh, Scotland)

Published: October 22, 2024

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 02, 2024

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Journal: Frontiers in oncology

Published: January 22, 2024

Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 09, 2023

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

[18F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.

De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.

Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.